CRISPR-Cas9-engineered TGFbRII-deleted anti-EGFR CAR T cells

{
  "id": "MLC-T-ONC-012806",
  "term": "CRISPR-Cas9-engineered TGFbRII-deleted anti-EGFR CAR T cells",
  "field": "Oncology and biomedicine",
  "definition": "A preparation of human T lymphocytes genetically engineered to express an anti-epidermal growth factor receptor (EGFR) chimeric antigen receptor (CAR) gene and gene-edited with the clustered regularly interspaced short palindromic repeats (CRISPR)-Cas9 nuclease complex to disrupt expression of transforming growth factor-beta receptor II (TGFbRII), with potential immunostimulatory and antineoplastic activities. Upon administration, the CRISPR-Cas9 engineered TGFbRII-deleted anti-EGFR CAR T cells target and bind to the EGFR antigen on tumor cell surfaces; subsequently, EGFR-expressing tumor cells may be lysed. EGFR, overexpressed by a variety of cancer cell types, plays a key role in tumor cell proliferation, tumor angiogenesis and radio- and chemoresistance. By knocking out the expression of TGFbRII, the immunosuppressive cytokine TGF-beta is unable to bind to the T cells and prevent the activation of the T cells. TGF-beta contributes to the immunosuppressive nature of the tumor microenvironment (TME), and plays a key role in promoting tumor initiation, metastasis, and suppressing anti-tumor immunity.",
  "synonyms": [
    "TGFbeta receptor II-Kknockout EGFR CAR T cells",
    "TGFbR-KO CAR-EGFR T cells"
  ],
  "references": [
    "National Cancer Institute Thesaurus"
  ],
  "url": "https://mlchart.com/terminology/oncology/crispr-cas9-engineered-tgfbrii-deleted-anti-egfr-car-t-cells/"
}